Skip to main content
Download PDF
Download ePub

Erratum to: Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study

Annals of General Psychiatry volume 8, Article number: 15 (2009) Cite this article

The Original Article was published on 28 August 2008

Abstract

Correction to Geitona M, Kousoulakou H, Ollandezos M, Athanasakis K, Papanicolaou S and Kyriopoulos I: Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Annals of General Psychiatry 2008, 7:16. This correction reports changes in the values listed for Ziprasidone and Aripiprazole in Table Ten.

Correction

Following the publication of our article [1], it has come to our attention that there was an error with the values listed for Ziprasidone and Aripiprazole in Table Ten. Table Ten should therefore appear as shown in this correction (Table 1).

Table 1 Mean annual number of stable days and cost per patient by pharmaceutical treatment.
Full size table

References

  1. Geitona M, Kousoulakou H, Ollandezos M, Athanasakis K, Papanicolaou S, Kyriopoulos I: Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Annals of General Psychiatry. 2008, 7: 16-10.1186/1744-859X-7-16.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Economics, University of Thessaly, Magnissias 96, Dionyssos, 14576, Greece

    Maria Geitona

  2. Institute for Economic and Industrial Research, Tsami Karatasi 11, 117 42, Athens, Greece

    Hara Kousoulakou

  3. Department of Health Economics, National School of Public Health, Aleksandra's Avenue 196, 11521, Athens, Greece

    Markos Ollandezos, Kostas Athanasakis & Ioannis Kyriopoulos

  4. Janssen-Cilag Pharmaceutical SACI, Eirinis Avenue 56, 15121, Pefki, Athens, Greece

    Sotiria Papanicolaou

Authors
  1. Maria Geitona
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hara Kousoulakou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Markos Ollandezos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kostas Athanasakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sotiria Papanicolaou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ioannis Kyriopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sotiria Papanicolaou.

Additional information

The online version of the original article can be found at 10.1186/1744-859X-7-16

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Geitona, M., Kousoulakou, H., Ollandezos, M. et al. Erratum to: Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Ann Gen Psychiatry 8, 15 (2009). https://doi.org/10.1186/1744-859X-8-15

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/1744-859X-8-15

Annals of General Psychiatry

ISSN: 1744-859X